The FDA Verified Service market has emerged as a critical segment in the healthcare and food industries, providing essential validation of products that meet the stringent requirements set forth by the Food and Drug Administration (FDA). This service is particularly valued for its ability to assure consumers and bus

All BPD data on Open Baltimore is preliminary data and subject to change. The information presented through Open Baltimore represents Part I victim based crime data. The data do not represent statistics submitted to the FBI's Uniform Crime Report (UCR); therefore any comparisons are strictly prohibited. For further clarification of UCR data, please visit http://www.fbi.gov/about-us/cjis/ucr/ucr. Please note that this data is preliminary and subject to change. Prior month data is likely to show changes when it is refreshed on a monthly basis. All data is geocoded to the approximate latitude/longitude location of the incident and excludes those records for which an address could not be geocoded. Any attempt to match the approximate location of the incident to an exact address is strictly prohibited.

This data package contains information on adverse Food Events 2004 to 2018, ingredient database of dietary supplements, International Food Consumption Database and Nutrition Assistance Program Participation and Cost Database.

Statistically significant difference between weekday (Mon-Fri) and weekend (Sat-Sun) loads using the Wilcox test (p-value < 0.001)*No statistically significant difference between weekday (Mon-Fri) and weekend (Sat-Sun) loads using the Wilcox test(p-value = 0.369)The data sets supporting the table are freely available [17].Wastewater drug loads for 42 European cities throughout the week.

This dataset provides statistics on the number of food poisoning cases at food consumption locations after 1981, for the use of the general public, businesses, academic institutions, etc.

• Akaike's information criterion.a Number taken from http://en.wikipedia.org/wiki/List_of_countries_by_GDP_%28nominal%29_per_capita.b Number of inhabitants in city divided by the urban area in square kilometres.c Number of inhabitants in city divided by the number of inhabitants in the country.Multiple regression analyses with functional principal component scores for ecstasy (MDMA) as dependent variable and longitude, latitude, gross domestic product, population density and relative size of the city as explanatory variables.

This dataset provides statistics on the number of cases and causative substances of food poisoning incidents after the year 1981. It is intended for use by the general public, businesses, academic institutions, and others.

This dataset provides annual statistics on violations found during on-site audits of controlled drugs and is updated annually for use by the general public and other users.

The Fully Differential Amplifier (FDA) market is witnessing significant growth, driven by the increasing demand for high-performance audio and signal processing applications across various industries. Fully Differential Amplifiers are essential components in modern electronic circuits, providing improved noise immun

Overall mean of the log-transformed data throughout the seven day week.*Difference: mean of the log-transformed data (weekend) minus mean of the log-transformed data (weekdays).Pearson correlation coefficients between FPC scores for the ecstasy (MDMA) loads and simple summary measures.

• Akaike's information criterion.a Number taken from http://en.wikipedia.org/wiki/List_of_countries_by_GDP_%28nominal%29_per_capita.b Number of inhabitants in city divided by the urban area in square kilometres.c Number of inhabitants in city divided by the number of inhabitants in the country.Multiple regression analyses with functional principal component scores for amphetamine as dependent variable and longitude, latitude, gross domestic product, population density and size of the city as explanatory variables.

Provide non-compliant food, drug and cosmetic advertising inquiries system https://pmds.fda.gov.tw/illegalad/

Mexico Consumer Price Index (CPI): FDA: FHA: Furniture data was reported at 121.485 16Dec2010-31Dec2010=100 in Jul 2018. This records an increase from the previous number of 120.485 16Dec2010-31Dec2010=100 for Jun 2018. Mexico Consumer Price Index (CPI): FDA: FHA: Furniture data is updated monthly, averaging 70.316 16Dec2010-31Dec2010=100 from Jan 1980 (Median) to Jul 2018, with 463 observations. The data reached an all-time high of 121.485 16Dec2010-31Dec2010=100 in Jul 2018 and a record low of 0.131 16Dec2010-31Dec2010=100 in Jan 1980. Mexico Consumer Price Index (CPI): FDA: FHA: Furniture data remains active status in CEIC and is reported by National Institute of Statistics and Geography. The data is categorized under Global Database’s Mexico – Table MX.I004: Consumer Price Index: Second Half December 2010=100.

This dataset is comprised of data submitted to HCAI by prescription drug manufacturers for wholesale acquisition cost (WAC) increases that exceed the statutorily-mandated WAC increase threshold of an increase of more than 16% above the WAC of the drug product on December 31 of the calendar year three years prior to the current calendar year. This threshold applies to prescription drug products with a WAC greater than $40 for a course of therapy. Required WAC increase reports are to be submitted to HCAI within a month after the end of the quarter in which the WAC increase went into effect. Please see the statute and regulations for additional information regarding reporting thresholds and report due dates.

Key data elements in this dataset include the National Drug Code (NDC) maintained by the FDA, narrative descriptions of the reasons for the increase in WAC, and the five-year history of WAC increases for the NDC. A WAC Increase Report consists of 27 data elements that have been divided into two separate Excel data sets: Prescription Drug WAC Increase and Prescription Drug WAC Increase – 5 Year History. The datasets include manufacturer WAC Increase Reports received since January 1, 2019. The Prescription Drugs WAC Increase dataset consists of the information submitted by prescription drug manufacturers that pertains to the current WAC increase of a given report, including the amount of the current increase, the WAC after increase, and the effective date of the increase. The Prescription Drugs WAC Increase – 5 Year History dataset consists of the information submitted by prescription drug manufacturers for the data elements that comprise the 5-year history of WAC increases of a given report, including the amount of each increase and their effective dates.

There are two types of WAC Increase datasets below: Monthly and Annual. The Monthly datasets include the data in completed reports submitted by manufacturers for calendar year 2025, as of November 7, 2025. The Annual datasets include data in completed reports submitted by manufacturers for the specified year. The datasets may include reports that do not meet the specified minimum thresholds for reporting.

The Quick Guide explaining how to link the information in each data set to form complete reports is here: https://hcai.ca.gov/wp-content/uploads/2024/03/QuickGuide_LinkingTheDatasets.pdf

The program regulations are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/CTRx-Regulations-Text.pdf

The data format and file specifications are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/Format-and-File-Specifications-version-2.0-ada.pdf

DATA NOTES: Due to recent changes in Excel, it is not recommended that you save these files to .csv format. If you do, when importing back into Excel the leading zeros in the NDC number column will be dropped. If you need to save it into a different format other than .xlsx it must be .txt

Submitted reports that are still under review by HCAI are not included in these files.

DATA UPDATES: Drug manufacturers may submit WAC Increase reports to HCAI for price increases from previous quarters. CTRx staff update the posted datasets monthly for current year data and as needed for previous years. Please check the 'Data last updated' date on each dataset page to ensure you are viewing the most current data.

Due to regulatory changes that went into effect April 1, 2024, reports submitted prior to April 1, 2024, will include the data field "Unit Sales Volume in US" and reports submitted on or after April 1, 2024, will instead include "Total Volume of Gross Sales in US Dollars".

Update — December 7, 2014. – Evidence-based medicine (EBM) is not working for many reasons, for example: 1. Incorrect in their foundations (paradox): hierarchical levels of evidence are supported by opinions (i.e., lowest strength of evidence according to EBM) instead of real data collected from different types of study designs (i.e., evidence). http://dx.doi.org/10.6084/m9.figshare.1122534 2. The effect of criminal practices by pharmaceutical companies is only possible because of the complicity of others: healthcare systems, professional associations, governmental and academic institutions. Pharmaceutical companies also corrupt at the personal level, politicians and political parties are on their payroll, medical professionals seduced by different types of gifts in exchange of prescriptions (i.e., bribery) which very likely results in patients not receiving the proper treatment for their disease, many times there is no such thing: healthy persons not needing pharmacological treatments of any kind are constantly misdiagnosed and treated with unnecessary drugs. Some medical professionals are converted in K.O.L. which is only a puppet appearing on stage to spread lies to their peers, a person supposedly trained to improve the well-being of others, now deceits on behalf of pharmaceutical companies. Probably the saddest thing is that many honest doctors are being misled by these lies created by the rules of pharmaceutical marketing instead of scientific, medical, and ethical principles. Interpretation of EBM in this context was not anticipated by their creators. “The main reason we take so many drugs is that drug companies don’t sell drugs, they sell lies about drugs.” ―Peter C. Gøtzsche “doctors and their organisations should recognise that it is unethical to receive money that has been earned in part through crimes that have harmed those people whose interests doctors are expected to take care of. Many crimes would be impossible to carry out if doctors weren’t willing to participate in them.” —Peter C Gøtzsche, The BMJ, 2012, Big pharma often commits corporate crime, and this must be stopped. Pending (Colombia): Health Promoter Entities (In Spanish: EPS ―Empresas Promotoras de Salud).

1. Misinterpretations New technologies or concepts are difficult to understand in the beginning, it doesn’t matter their simplicity, we need to get used to new tools aimed to improve our professional practice. Probably the best explanation is here in these videos (credits to Antonio Villafaina for sharing these videos with me). English https://www.youtube.com/watch?v=pQHX-SjgQvQ&w=420&h=315 Spanish https://www.youtube.com/watch?v=DApozQBrlhU&w=420&h=315 ----------------------- Hypothesis: hierarchical levels of evidence based medicine are wrong Dear Editor, I have data to support the hypothesis described in the title of this letter. Before rejecting the null hypothesis I would like to ask the following open question:Could you support with data that hierarchical levels of evidence based medicine are correct? (1,2) Additional explanation to this question: – Only respond to this question attaching publicly available raw data.– Be aware that more than a question this is a challenge: I have data (i.e., evidence) which is contrary to classic (i.e., McMaster) or current (i.e., Oxford) hierarchical levels of evidence based medicine. An important part of this data (but not all) is publicly available. References
2. Ramirez, Jorge H (2014): The EBM challenge. figshare. http://dx.doi.org/10.6084/m9.figshare.1135873
3. The EBM Challenge Day 1: No Answers. Competing interests: I endorse the principles of open data in human biomedical research Read this letter on The BMJ – August 13, 2014.http://www.bmj.com/content/348/bmj.g3725/rr/762595Re: Greenhalgh T, et al. Evidence based medicine: a movement in crisis? BMJ 2014; 348: g3725. _ Fileset contents Raw data: Excel archive: Raw data, interactive figures, and PubMed search terms. Google Spreadsheet is also available (URL below the article description). Figure 1. Unadjusted (Fig 1A) and adjusted (Fig 1B) PubMed publication trends (01/01/1992 to 30/06/2014). Figure 2. Adjusted PubMed publication trends (07/01/2008 to 29/06/2014) Figure 3. Google search trends: Jan 2004 to Jun 2014 / 1-week periods. Figure 4. PubMed publication trends (1962-2013) systematic reviews and meta-analysis, clinical trials, and observational studies.
   Figure 5. Ramirez, Jorge H (2014): Infographics: Unpublished US phase 3 clinical trials (2002-2014) completed before Jan 2011 = 50.8%. figshare.http://dx.doi.org/10.6084/m9.figshare.1121675 Raw data: "13377 studies found for: Completed | Interventional Studies | Phase 3 | received from 01/01/2002 to 01/01/2014 | Worldwide". This database complies with the terms and conditions of ClinicalTrials.gov: http://clinicaltrials.gov/ct2/about-site/terms-conditions Supplementary Figures (S1-S6). PubMed publication delay in the indexation processes does not explain the descending trends in the scientific output of evidence-based medicine. Acknowledgments I would like to acknowledge the following persons for providing valuable concepts in data visualization and infographics:
4. Maria Fernanda Ramírez. Professor of graphic design. Universidad del Valle. Cali, Colombia.
5. Lorena Franco. Graphic design student. Universidad del Valle. Cali, Colombia. Related articles by this author (Jorge H. Ramírez)
6. Ramirez JH. Lack of transparency in clinical trials: a call for action. Colomb Med (Cali) 2013;44(4):243-6. URL: http://www.ncbi.nlm.nih.gov/pubmed/24892242
7. Ramirez JH. Re: Evidence based medicine is broken (17 June 2014). http://www.bmj.com/node/759181
8. Ramirez JH. Re: Global rules for global health: why we need an independent, impartial WHO (19 June 2014). http://www.bmj.com/node/759151
9. Ramirez JH. PubMed publication trends (1992 to 2014): evidence based medicine and clinical practice guidelines (04 July 2014). http://www.bmj.com/content/348/bmj.g3725/rr/759895 Recommended articles
10. Greenhalgh Trisha, Howick Jeremy,Maskrey Neal. Evidence based medicine: a movement in crisis? BMJ 2014;348:g3725
11. Spence Des. Evidence based medicine is broken BMJ 2014; 348:g22
12. Schünemann Holger J, Oxman Andrew D,Brozek Jan, Glasziou Paul, JaeschkeRoman, Vist Gunn E et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies BMJ 2008; 336:1106
13. Lau Joseph, Ioannidis John P A, TerrinNorma, Schmid Christopher H, OlkinIngram. The case of the misleading funnel plot BMJ 2006; 333:597
14. Moynihan R, Henry D, Moons KGM (2014) Using Evidence to Combat Overdiagnosis and Overtreatment: Evaluating Treatments, Tests, and Disease Definitions in the Time of Too Much. PLoS Med 11(7): e1001655. doi:10.1371/journal.pmed.1001655
15. Katz D. A-holistic view of evidence based medicinehttp://thehealthcareblog.com/blog/2014/05/02/a-holistic-view-of-evidence-based-medicine/ ---

Mexico Consumer Price Index (CPI): FDA: FHA: Appliances data was reported at 101.269 16Dec2010-31Dec2010=100 in Jul 2018. This records an increase from the previous number of 100.840 16Dec2010-31Dec2010=100 for Jun 2018. Mexico Consumer Price Index (CPI): FDA: FHA: Appliances data is updated monthly, averaging 97.026 16Dec2010-31Dec2010=100 from Jan 1980 (Median) to Jul 2018, with 463 observations. The data reached an all-time high of 107.166 16Dec2010-31Dec2010=100 in Apr 2001 and a record low of 0.295 16Dec2010-31Dec2010=100 in Jan 1980. Mexico Consumer Price Index (CPI): FDA: FHA: Appliances data remains active status in CEIC and is reported by National Institute of Statistics and Geography. The data is categorized under Global Database’s Mexico – Table MX.I004: Consumer Price Index: Second Half December 2010=100.

Biostatistics and Programming Services Market Outlook

According to our latest research, the global biostatistics and programming services market size was valued at USD 2.7 billion in 2024, and is expected to reach USD 6.6 billion by 2033, expanding at a robust CAGR of 10.3% during the forecast period. The primary growth driver for this market is the increasing complexity of clinical trials and the surging demand for data-driven decision-making in drug development and regulatory submissions. As biostatistics and programming become essential components in ensuring the accuracy, validity, and regulatory compliance of clinical data, the market continues to experience significant expansion across the globe.

Several key factors are fueling the rapid growth of the biostatistics and programming services market. The increasing volume and complexity of clinical trials, driven by the rise of chronic diseases and the need for novel therapeutics, have necessitated the adoption of advanced statistical methodologies and programming solutions. Pharmaceutical and biotechnology companies are investing heavily in research and development, often outsourcing their biostatistics and programming needs to specialized service providers to ensure efficiency, compliance, and data integrity. The evolution of clinical research from traditional randomized controlled trials to adaptive and decentralized trial designs has further amplified the need for robust statistical analysis and programming expertise. This trend is expected to continue as the healthcare sector embraces digital transformation and data-centric approaches.

Another significant growth factor is the increasing regulatory scrutiny and demand for transparency in clinical data submissions. Regulatory agencies such as the FDA, EMA, and PMDA have established stringent guidelines for data management, statistical analysis, and programming, compelling pharmaceutical and biotechnology companies to seek expert assistance to meet these requirements. The growing emphasis on real-world evidence (RWE) and post-marketing surveillance studies also necessitates comprehensive biostatistical support, as companies strive to demonstrate the safety and efficacy of their products in diverse patient populations. As a result, the demand for specialized biostatistics and programming services is expected to rise steadily, particularly in light of evolving regulatory landscapes and the increasing complexity of clinical data.

Technological advancements are also playing a pivotal role in shaping the growth trajectory of the biostatistics and programming services market. The adoption of artificial intelligence (AI), machine learning, and advanced analytics tools has revolutionized data management, statistical programming, and clinical data analysis. These technologies enable faster, more accurate, and scalable solutions, allowing service providers to deliver higher value to their clients. Moreover, the integration of electronic data capture (EDC) systems, cloud-based platforms, and real-time analytics has enhanced the efficiency and reliability of biostatistics and programming services. As the industry continues to innovate, the adoption of these advanced technologies is expected to further accelerate market growth, offering new opportunities for service providers and end-users alike.

From a regional perspective, North America currently dominates the global biostatistics and programming services market, accounting for the largest share in 2024. This is attributed to the presence of leading pharmaceutical and biotechnology companies, well-established healthcare infrastructure, and a favorable regulatory environment. Europe follows closely, driven by increasing R&D investments and a strong focus on clinical research. The Asia Pacific region is emerging as a key growth market, propelled by expanding clinical trial activity, rising healthcare expenditure, and the growing presence of contract research organizations (CROs). As these regions continue to invest in healthcare innovation, the demand for biostatistics and programming services is expected to grow substantially, further strengthening the global market outlook.

Mexico Consumer Price Index (CPI): FDA: FHA: Appliances: Electronic: Televisions data was reported at 84.741 16Dec2010-31Dec2010=100 in Jul 2018. This records an increase from the previous number of 84.540 16Dec2010-31Dec2010=100 for Jun 2018. Mexico Consumer Price Index (CPI): FDA: FHA: Appliances: Electronic: Televisions data is updated monthly, averaging 102.942 16Dec2010-31Dec2010=100 from Jul 2002 (Median) to Jul 2018, with 193 observations. The data reached an all-time high of 114.605 16Dec2010-31Dec2010=100 in Jul 2002 and a record low of 84.540 16Dec2010-31Dec2010=100 in Jun 2018. Mexico Consumer Price Index (CPI): FDA: FHA: Appliances: Electronic: Televisions data remains active status in CEIC and is reported by National Institute of Statistics and Geography. The data is categorized under Global Database’s Mexico – Table MX.I004: Consumer Price Index: Second Half December 2010=100.

This statistic depicts the results of a 2016 survey in which U.S. adults were asked if they believed certain behaviors were very likely to cause food poisoning. In that year, 40 percent of respondents believed that eating meat or chicken that has not been thoroughly cooked is very likely to cause food poisoning.

Mexico Consumer Price Index (CPI): FDA: HCA: HHT: Others data was reported at 131.679 16Dec2010-31Dec2010=100 in Jul 2018. This records a decrease from the previous number of 132.368 16Dec2010-31Dec2010=100 for Jun 2018. Mexico Consumer Price Index (CPI): FDA: HCA: HHT: Others data is updated monthly, averaging 79.986 16Dec2010-31Dec2010=100 from Jan 1995 (Median) to Jul 2018, with 283 observations. The data reached an all-time high of 132.368 16Dec2010-31Dec2010=100 in Jun 2018 and a record low of 23.106 16Dec2010-31Dec2010=100 in Jan 1995. Mexico Consumer Price Index (CPI): FDA: HCA: HHT: Others data remains active status in CEIC and is reported by National Institute of Statistics and Geography. The data is categorized under Global Database’s Mexico – Table MX.I004: Consumer Price Index: Second Half December 2010=100.